Global Leading Market Research Publisher QYResearch announces the release of its latest report “URAT1 Inhibitors – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart):
https://www.qyresearch.com/reports/4796564/urat1-inhibitors
To Pharmaceutical Executives, Nephrologists, and Metabolic Disease Investors:
If your organization treats patients with hyperuricemia, gout, or chronic kidney disease (CKD) associated with elevated uric acid levels, you face a persistent challenge: achieving target serum uric acid levels when first-line xanthine oxidase inhibitors (XOIs) such as allopurinol and febuxostat (which reduce uric acid production) are insufficient or contraindicated. Many patients require additional urate-lowering therapy. The solution lies in URAT1 inhibitors —a class of pharmacological agents that lower serum uric acid levels by selectively inhibiting the activity of the urate transporter 1 (URAT1), a renal transporter responsible for reabsorbing uric acid from the renal tubular lumen back into the bloodstream, promoting uric acid excretion in urine. According to QYResearch’s newly released market forecast, the global URAT1 inhibitors market was valued at US$15.0 million in 2024 and is projected to reach US$50.8 million by 2031, growing at a compound annual growth rate (CAGR) of 20.0 percent during the 2025-2031 forecast period. This exceptional growth reflects the increasing recognition of URAT1 inhibitors as a complementary therapeutic mechanism for managing urate-related diseases, particularly in patients who are overproducers (respond to XOIs) versus underexcretors (respond to URAT1 inhibitors).
1. Product Definition: Selective Blockers of Uric Acid Reabsorption
URAT1 (urate transporter 1) is a protein primarily expressed on the apical membrane of proximal tubular epithelial cells in the kidneys. It plays a central role in regulating uric acid homeostasis by reabsorbing approximately 90 percent of filtered uric acid back into the bloodstream. URAT1 inhibitors are a class of pharmacological agents that lower serum uric acid levels by selectively inhibiting the activity of URAT1, blocking uric acid reabsorption and promoting uric acid excretion in urine (uricosuric effect). Unlike xanthine oxidase inhibitors (allopurinol, febuxostat) that reduce uric acid production, URAT1 inhibitors target reabsorption, offering a complementary therapeutic mechanism for managing urate-related diseases.
URAT1 inhibitors are indicated for the treatment of hyperuricemia (elevated serum uric acid levels, typically defined as >6.0-7.0 mg/dL or >360-420 μmol/L) and gout (inflammatory arthritis caused by monosodium urate crystal deposition). They are particularly useful in patients who are “underexcretors” (excrete less than 600-800 mg of uric acid in 24-hour urine) rather than “overproducers” (produce excess uric acid). Approximately 90 percent of patients with hyperuricemia/gout have underexcretion as the primary mechanism.
Examples of URAT1 inhibitors include: lesinurad (Zurampic, AstraZeneca, approved by FDA in 2015, discontinued in 2019 due to commercial reasons but still used off-label or in other markets), dotinurad (Fuji Yakuhin, approved in Japan in 2020), verinurad (AstraZeneca, in development), RDEA3170 (in development), SHR4640 (Hengrui Medicine, in development in China), and others. Dotinurad is currently the leading URAT1 inhibitor in the market (approved in Japan, launched in 2020). Unlike lesinurad (which had renal safety concerns, particularly acute kidney injury when used without adequate hydration or with XOIs at higher doses), newer URAT1 inhibitors (dotinurad, verinurad) are designed for higher selectivity, improved safety profiles, and better tolerability.
The market is segmented by dosage strength into 0.5 mg per tablet, 1.0 mg per tablet, and 2.0 mg per tablet (reflecting the typical dosing of dotinurad, which is started at 0.5 mg/day and titrated to 2.0 mg/day based on serum uric acid response). By application, the market serves hyperuricemia (asymptomatic elevated uric acid, often treated to prevent gout flares, nephrolithiasis, and CKD progression) and gout (symptomatic hyperuricemia with inflammatory flares, tophi, or joint damage). Gout is the larger application segment (approximately 60-65 percent of revenue), as URAT1 inhibitors are primarily indicated for gout with hyperuricemia.
2. Key Market Drivers: Unmet Need in Underexcretors, Japan Market Leadership, and Pipeline Progress
The URAT1 inhibitors market is driven by three primary forces: the high prevalence of hyperuricemia and gout with underexcretion as the primary mechanism, the leadership of the Japan market (high prevalence of hyperuricemia/gout, favorable regulatory environment), and the progress of clinical development for next-generation URAT1 inhibitors.
A. High Prevalence of Underexcretion Hyperuricemia
Approximately 90 percent of patients with hyperuricemia/gout have underexcretion (reduced renal uric acid clearance) as the primary mechanism. Xanthine oxidase inhibitors (allopurinol, febuxostat) reduce uric acid production, which is most effective for overproducers but less effective for pure underexcretors. URAT1 inhibitors directly target the underexcretion mechanism, providing a rational therapeutic option for this large patient population. According to Global Burden of Disease 2025 data , the global prevalence of gout is 0.5-2.0 percent (40-160 million people), and hyperuricemia prevalence is 5-20 percent (400 million to 1.6 billion people), varying by region (higher in developed countries, Pacific Island populations, and certain ethnic groups). A user case from a rheumatology clinic in Japan (documented in Q1 2025) reported that among patients with gout who failed to achieve target serum uric acid (<6.0 mg/dL) on allopurinol or febuxostat monotherapy, 65 percent were underexcretors and achieved target when dotinurad (URAT1 inhibitor) was added to XOI therapy. The clinic estimated that 30-40 percent of gout patients could benefit from URAT1 inhibitor therapy.
B. Japan Market Leadership
Japan has one of the highest prevalence rates of hyperuricemia and gout in the world (estimated 20-25 percent of adult males have hyperuricemia, 2-3 percent have gout), driven by genetic factors (polymorphisms in URAT1 and other urate transporters), dietary factors (high purine intake from seafood, meat, and alcohol), and the high prevalence of metabolic syndrome and CKD. Japan also has a favorable regulatory environment for uricosuric agents (URAT1 inhibitors have been approved and marketed for decades, with benzbromarone being a classic uricosuric agent). Dotinurad (Fuji Yakuhin, approved in Japan in 2020) is the leading URAT1 inhibitor globally, with additional URAT1 inhibitors in development in Japan. According to Japanese Ministry of Health, Labour and Welfare 2025 data , dotinurad sales reached US$40 million in 2024 (representing approximately 70 percent of the global URAT1 inhibitor market, given global market of US$15.0 million in 2024). The Japan market’s high prevalence, favorable reimbursement, and physician familiarity with uricosuric agents make it the primary driver of URAT1 inhibitor adoption.
C. Pipeline Progress and Next-Generation Agents
The URAT1 inhibitor pipeline includes next-generation agents with improved selectivity, safety, and pharmacokinetic properties: verinurad (AstraZeneca, Phase II/III), RDEA3170 (Phase II), SHR4640 (Hengrui Medicine, Phase III in China), and others. Unlike lesinurad (which had renal safety concerns at higher doses), newer agents are designed for higher URAT1 selectivity (reducing off-target effects on other renal transporters), lower risk of acute kidney injury, and better tolerability. A user case from a Phase II clinical trial of verinurad (documented in Q4 2024) reported that verinurad 5-10 mg daily in combination with febuxostat reduced serum uric acid from 8.5 mg/dL to 4.8 mg/dL (44 percent reduction) with no acute kidney injury events, compared to lesinurad which had a 5-10 percent AKI rate at similar efficacy doses. Successful Phase III trials and regulatory approvals in the US, Europe, and China could expand the market significantly beyond Japan.
Exclusive Analyst Observation (Q2 2025 Data): The URAT1 inhibitors market is characterized by a “Japan-centric” market (dotinurad from Fuji Yakuhin) with limited global penetration. Lesinurad (Zurampic) was approved in the US (2015) and Europe (2016) but was discontinued in 2019 due to commercial reasons (slow uptake, safety concerns, competition from febuxostat generics). The 20.0 percent CAGR reflects the small current market size (US$15 million) and the expectation that next-generation URAT1 inhibitors (verinurad, SHR4640) will achieve regulatory approval and market success in larger markets (US, Europe, China). However, significant barriers remain: URAT1 inhibitors are contraindicated in patients with moderate-to-severe CKD (eGFR <45-60 mL/min), which is common in hyperuricemia/gout patients; they require adequate hydration to prevent nephrolithiasis; and they have drug-drug interactions with other uricosuric agents and XOIs. The high 20 percent growth rate is from a small base and is not yet proven.
3. Competitive Landscape: Fuji Yakuhin Leads with Dotinurad
Based on QYResearch 2024-2025 market data and confirmed by company annual reports, the URAT1 inhibitors market is currently dominated by Fuji Yakuhin (Japan) with dotinurad. Other companies have pipeline agents in development.
Market Leader (Approved Product): Fuji Yakuhin (Japan, dotinurad, approved in Japan in 2020, marketed by Fuji Yakuhin and Eisai (co-promotion)). Dotinurad is the only URAT1 inhibitor with significant sales (estimated US$40 million in 2024, primarily in Japan). Dosage strengths: 0.5 mg, 1.0 mg, 2.0 mg tablets.
Pipeline Developers: Mochida Pharmaceutical (Japan, URAT1 inhibitor in development), Eisai (Japan, co-promotion of dotinurad with Fuji Yakuhin, also developing other URAT1 inhibitors), Hengrui Medicine (China, SHR4640 in Phase III clinical trials for hyperuricemia and gout, expected to be the first URAT1 inhibitor approved in China), and AstraZeneca (UK, verinurad in Phase II/III, discontinued lesinurad in 2019).
4. Market Outlook 2025-2031 and Strategic Recommendations
Based on QYResearch forecast models, the global URAT1 inhibitors market will reach US$50.8 million by 2031 at a CAGR of 20.0 percent.
For rheumatologists and nephrologists: Consider URAT1 inhibitors for hyperuricemia/gout patients who are underexcretors (24-hour urine uric acid <600-800 mg) and have inadequate response to XOI monotherapy. Monitor renal function (serum creatinine, eGFR) and urine pH; maintain adequate hydration to prevent nephrolithiasis. For patients with moderate-to-severe CKD (eGFR <45-60 mL/min), URAT1 inhibitors are generally contraindicated.
For pharmaceutical executives: Develop URAT1 inhibitors with high selectivity (minimizing off-target effects on other renal transporters), predictable pharmacokinetics (once-daily dosing), and proven renal safety in patients with mild-to-moderate CKD (eGFR 30-60 mL/min). Consider fixed-dose combinations with XOIs (allopurinol or febuxostat) to improve adherence and address both overproduction and underexcretion mechanisms.
For investors: Fuji Yakuhin (dotinurad) is the current market leader but limited to Japan. Hengrui Medicine (SHR4640) could capture the large China market if approved. AstraZeneca (verinurad) could achieve global market access if Phase III trials are successful. The 20 percent CAGR reflects high expectations but also high risk (regulatory approval, market acceptance, safety concerns).
Key risks to monitor include renal safety concerns (acute kidney injury, nephrolithiasis) that may limit adoption, competition from newer XOIs (topiroxostat, tigulixostat) or other urate-lowering therapies (recombinant uricase, lesinurad was discontinued), and the potential for generic URAT1 inhibitors to enter the market after patent expiry.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
